NeckEpur develops solutions to improve the management of patients likely to be exposed to medical devices used in extracorporeal circulation (MDEC): • We have a patented method to measure the phenomenon of sequestration by MDEC • We are developing new medical devices to specifically target molecules of interest such as contaminants in the context of EIDs and NRBC. • We are developing new treatments based on blood purification technologies through a new paradigm to capture circulating molecules and offer alternative treatments. NeckEpur is a set of activities aiming at assessing drug sequestration in medical devices with extra corporeal circulation with filters, including continuous renal replacement therapy (CCRT) and extracorporeal oxygenation (ECMO) for supporting either respiratory failure (veno-venous) or cardiac failure (arteriovenous). Sequestration has been reported previously, but the clinical relevance of the studies available until now seems to be very questionable. After more than 3 years of research, NeckEpur is now able to prove sequestration, quantify and characterize the mechanisms governing pharmacokinetic modifications of drugs associated with medical devices such as CCRT and ECMO. This is made possible by an extremely robust and reproducible in vitro model that we have developed. NeckEpur was incorporated early 2022 based on the results of Pr. Frédéric Baud (Necker Hospital - AP-HP, Paris) with the support of AP-HP.
